pindolol has been researched along with oxazepam in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghuloum, AM; Jain, AN; Sage, CR | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Ertl, P; Rohde, B; Selzer, P | 1 |
| Artursson, P; Luthman, K; Norinder, U; Stenberg, P | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Caron, G; Ermondi, G | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Goch, JH; Kowalski, J; Tkaczewski, W; Wichan, P | 1 |
| Maftouh, M; Mangelings, D; Massart, DL; Vander Heyden, Y | 1 |
1 review(s) available for pindolol and oxazepam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for pindolol and oxazepam
| Article | Year |
|---|---|
[Ergometric test in sympatheticotonia after administration of propranolol, pindolol, verapamil and oxazepam].
Topics: Adolescent; Adrenergic Fibers; Adult; Clinical Trials as Topic; Exercise Test; Heart; Heart Failure; Humans; Male; Oxazepam; Pindolol; Propranolol; Verapamil | 1980 |
13 other study(ies) available for pindolol and oxazepam
| Article | Year |
|---|---|
Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.
Topics: Drug Design; Intestinal Absorption; Models, Molecular; Pharmaceutical Preparations; Structure-Activity Relationship | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
Topics: Biological Availability; Biological Transport; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Reproducibility of Results | 2000 |
Experimental and computational screening models for the prediction of intestinal drug absorption.
Topics: Biological Transport; Carbon Radioisotopes; Cell Line; Cell Membrane; Cell Membrane Permeability; Ciprofloxacin; Computational Biology; Drug Design; Foscarnet; Humans; Hydrogen Bonding; Intestinal Absorption; Intestinal Mucosa; Lactulose; Mannitol; Models, Biological; Raffinose; Surface Properties; Tritium; Verapamil | 2001 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Enantioseparations by capillary electro-chromatography: differences exhibited by normal- and reversed-phase versions of polysaccharide stationary phases.
Topics: Amylose; Carbamates; Cellulose; Chromatography, Micellar Electrokinetic Capillary; Hydrogen-Ion Concentration; Indicators and Reagents; Oxazepam; Phenylcarbamates; Pindolol; Polysaccharides; Praziquantel; Stereoisomerism; Tetramisole | 2004 |